research

In a new article published in the journal Trends in Biotechnology, Korean researchers suggest that diseases of the central nervous system (CNS) might be better studied using compact, accessible chip technology than in current methods. The report, titled “Central Nervous System and its Disease…

In a recent study published in the journal BMJ Open, a research team explored the use of fatigue management strategies in patients with multiple sclerosis (MS) who attended a group-based fatigue management program. The Multiple Sclerosis Council for Clinical Practice Guidelines defines fatigue as “a subjective lack…

In a recent study published in the journal PLOS One, a team of researchers explored the differences in cognitive performance and magnetic resonance imaging (MRI) correlates of cognitive deficits in patients with relapsing-remitting multiple sclerosis (RRMS) and patients with primary progressive multiple sclerosis (PPMS) to underscore the importance…

A recent study published in the journal Science Translational Medicine provided new insights into the role of B cells in multiple sclerosis (MS), and points to a specific line of possible new therapies. The study is entitled “Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell…

A new study from Sweden indicates that vitamin D could help protect nerve cells (neurons) in multiple sclerosis (MS). The report, titled “Vitamin D and axonal injury in multiple sclerosis,“ was published on October 13, 2015, in the Multiple Sclerosis Journal. Scientists have demonstrated, in…

Results from a recent study published in the journal Immunity indicate that dietary fat has an influence in the duration and severity of autoimmune flare-ups in a mouse model of multiple sclerosis. The team of researchers also showed that adjusting the length of the fatty acids consumed by…

In a recent study published in the International Journal of MS Care, a team of researchers determined that among patients with multiple sclerosis (MS), fatigue was the most common symptom associated with the decision to leave work or reduce the employment status. According to the researchers, comprehensive…

In a recent study entitled “Equivalent Gene Expression Profiles between Glatopa™ and Copaxone®,” authors determined potential differences in treatment responses by investigating the gene expression profile of two approved treatments for relapsing forms of multiple sclerosis – Copaxone and Glatopa. Both of these MS therapies are glatiramer…

A recently published study in the journal PLOS One reported a new tool to assess risk knowledge in multiple sclerosis (MS) patients. The study was conducted by an international team led by researchers at the University Medical Center Eppendorf in Hamburg, Germany, and is entitled “…

A new study published in the Journal of Biological Chemistry revealed novel potential inhibitors of specific proteins involved in the pathogenesis of cancer and autoimmune disorders, like multiple sclerosis. The study is entitled “Dual Targeting of the Chemokine Receptors CXCR4 and ACKR3 with Novel…

Adamas Pharmaceuticals, Inc., a pharmaceutical company focused on chronic conditions that affect the central nervous system, recently announced results from two non-clinical studies showing that the company’s product candidate ADS-5102 can be potentially applied as a treatment for multiple sclerosis (MS) symptoms. MS is a chronic, progressive neurodegenerative autoimmune…

Among the different therapeutic approaches being explored for treating MS, adult stem cell therapy continues to be one of the most discussed and anticipated in the MS community. “Stem cells” — the common term for undifferentiated, self-renewing proliferating cells — are currently being investigated for their ability to treat patients in a wide range of disease…

Researchers from the Gladstone Institutes have shown in a new study that fibrinogen, an important blood coagulation protein, can induce an autoimmune response in the central nervous system when the blood-brain barrier (BBB) is disrupted and blood proteins enter the brain. The study, entitled “Blood coagulation protein fibrinogen promotes…

A recent study of people with relapsing remitting multiple sclerosis (RRMS) found that high-dose oral vitamin D3 supplementation did not influence markers of inflammation. Inflammation is a reaction to bodily injury that may be over-activated in people with multiple sclerosis (MS). The article, titled “Vitamin D supplementation and systemic inflammation in…

A session titled “Late Breaking News” was featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 7-10, 2015, in Barcelona, Spain. At this session, Prof. Xavier Montalban from the Hospital Vall d’Hebron University in Barcelona presented data on the promising Genentech/Roche…

Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recently held in Barcelona, Spain (October 7 – 10, 2015). The first parallel session was entitled “Will…

Three parallel sessions concerning multiple sclerosis (MS) prevention, clinical phenotypes and magnetic resonance imaging (MRI) were featured at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), recently held in Barcelona, Spain (October 7 – 10, 2015). The first parallel session was entitled “Will MS…

A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros at a Satellite Symposia entitled “MS developments: transitioning evidence into clinical practice” presented by the company this morning at the 31st Congress of the European Committee for Treatment and…

A new study recently published in the journal Neurology: Neuroimmunology & Neuroinflammation revealed that the drug Cladribine does not increase the risk of cancer in patients with multiple sclerosis (MS) as previously thought. The study was led by researchers at Queen Mary University of London (QMUL)…

A Satellite Symposia entitled “Discovering a new world in MS” supported by Teva Neuroscience was held yesterday, October 8, at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), currently taking place in Barcelona, Spain, October 7 – 10, 2015. Prof. David Brassat…

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) is currently being held in Barcelona, from 7 to 10 of October, 2015. As the biggest scientific event focused on Multiple Sclerosis, researchers and clinicians from around the world, with more than 8,000 participants, gather…

New developments in the diagnosis and treatment of multiple sclerosis (MS) are being discussed at this year’s 31st annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The symposium, being held in Barcelona, Spain, will foster discussions about development of individualized therapies for MS patients through a more targeted and efficient…

Genzyme recently announced results from magnetic resonance imaging (MRI) analysis of participants in the Phase III TEMSO clinical trial showing that Aubagio® (teriflunomide) was able to slow the loss of brain volume (or atrophy) versus a placebo over two years in patients with relapsing multiple sclerosis (RMS). Brain volume loss (BVL)…

The world’s largest generic medicines manufacturer, Teva Pharmaceutical, is at the 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress currently ongoing in Barcelona, from October 7-10, 2015. Teva will be presenting the latest findings on its relapsing multiple sclerosis (MS) therapy COPAXONE® (glatiramer acetate injection), and product candidate for…

A number of studies have previously suggested a negative effect of high cholesterol levels on the development of brain lesions in patients with multiple sclerosis (MS), however, little is known about the effect of HDL (high-density lipoprotein) cholesterol, or “good” cholesterol, on MS. A team of scientists from the University…

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) begins today, October 7, 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress will focus heavily on Teaching Courses in several topics related to multiple sclerosis (MS)…

The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will start today, 7 October 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress is heavily focused on Teaching Courses in several topics related to multiple…

Icometrix, a leader in magnetic resonance imaging (MRI) biomarkers for multiple sclerosis (MS), has recently announced a collaboration agreement with Novartis Pharma AG regarding MSmetrix – a measurement tool especially designed to assess brain volume and atrophy, as well as existing, new or enlarging brain lesions in MS patients. Monitoring…

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors recently approved an $83 million grant to support 26 patient-centered, comparative effectiveness clinical research (CER) studies on a range of diseases and patient groups. Two of these grants, totaling $29.5 million, will fund research into the care of patients infected with hepatitis…

A new study recently published in the journal PLOS ONE revealed that high intensity exercise is safe and offers clinical benefits for patients with multiple sclerosis (MS). The study is entitled “High Intensity Exercise in Multiple Sclerosis: Effects on Muscle Contractile Characteristics and Exercise…